Ayala Pharmaceuticals, Inc. (ADXS) [Rocket]

Overview

Ayala Pharmaceuticals, Inc. (ADXS)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
09/29/2023	4/A	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
09/29/2023	3/A	Form 3/A - Initial statement of beneficial ownership of securities: [Amend]
08/10/2023	10-Q	Quarterly Report for the period ended June 30, 2023
08/01/2023	8-K	Quarterly results
02/08/2023	SC 13G	Redmile Group, LLC reports a 6.8% stake in AYALA PHARMACEUTICALS, Inc.
01/30/2023	NT 10-K	Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
01/30/2023	3	aMoon Growth Fund Limited Partnership (10% Owner) has filed a Form 3 on Ayala Pharmaceuticals, Inc.

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Oct-31-21	Oct-31-20	Oct-31-19	Oct-31-18	Oct-31-17	Oct-31-16	Oct-31-15	Oct-31-14
Revenues	3.2	0.3	20.9	6.1	12.0	4.0	0.0	1.0
Revenue growth	1180.6%	-98.8%	244.4%	-49.6%	201.2%		-100.0%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	3.2	0.3	20.9	6.1	12.0	4.0	0.0	1.0
Gross margin	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%		100.0%
Research and development	10.6	15.6	26.7	57.0	70.5	48.8	24.5	8.9
General and administrative	11.5	11.1	12.2	19.5	40.0	31.7	24.2	11.7
EBITA	-18.5	-26.1	-17.6	-70.0	-98.1	-76.2	-48.5	-19.4
EBITA margin	-571.4%	-10320.9%	-84.2%	-1154.4%	-815.5%	-1908.4%		-1936.3%
Amortization of intangibles	0.3	0.3	0.4	0.4	0.3	0.3	0.2	0.2
EBIT	-18.8	-26.4	-18.0	-70.4	-98.4	-76.5	-48.7	-19.5
EBIT margin	-579.8%	-10454.2%	-86.1%	-1160.8%	-818.3%	-1914.8%		-1953.9%
Pre-tax income	-17.8	-26.4	-16.6	-66.5	-97.8	-76.1	-48.6	-18.9
Income taxes	0.1	0.1	0.1	-16.8	31.0	-2.5	-1.6	-2.4
Tax rate				25.3%		3.3%	3.3%	12.5%
Net income	-17.9	-26.5	-16.6	-66.5	-93.4	-73.6	-47.0	-16.5
Net margin	-551.3%	-10462.1%	-79.5%	-1097.1%	-776.6%	-1841.3%		-1652.5%

Diluted EPS	($0.14)	($0.43)	($1.09)	($19.36)	($2.31)	($2.08)	($1.68)	($0.97)
Shares outstanding (diluted)	129.1	61.0	15.2	3.4	40.5	35.4	28.0	17.1

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.